Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2BTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3MPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PPARGSLC6A2SLC6A3SLC6A4SMOTYK2pol
The experimentally established mechanism targets of Maleic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A known ✓ | P08908 | 3/20 | 0.42 |
| ▸ | HTR2C known ✓ | P28335 | 3/20 | 0.42 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.42 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.42 |
| ▸ | HTR2A known ✓ | P28223 | 2/20 | 0.42 |
| ▸ | HTR2B known ✓ | P41595 | 2/20 | 0.42 |
| ▸ | DRD1 known ✓ | P21728 | 1/20 | 0.42 |
| ▸ | HTR4 known ✓ | Q13639 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 1.00 |
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | RAD52 | P43351 | 1/20 | 1.00 |
| ▸ | HTR6 | P50406 | 4/20 | 0.80 |
| ▸ | HTR7 | P34969 | 4/20 | 0.80 |
| ▸ | HTR1D | P28221 | 3/20 | 0.80 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.80 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.80 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.80 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.80 |
| ▸ | HTR3A | P46098 | 2/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL1320838 | 1.00 | NPSR1 (1.00) | NPSR1BLMRAD52HTR6HTR7 | |
| SCHEMBL399028 | 0.89 | HTR6 (1.00) | NPSR1BLMRAD52HTR6HTR7 | |
| SCHEMBL29361176 | 0.89 | HTR6 (1.00) | NPSR1BLMRAD52HTR6HTR7 | |
| Hydrochloric Acid SCHEMBL5791576 | 0.88 | HTR6 (0.97) | NPSR1BLMRAD52HTR6HTR7 | |
| SCHEMBL852745 | 0.80 | HSD17B10 (0.67) | NPSR1BLMRAD52HTR6HTR7 | |
| SCHEMBL11788979 | 0.79 | HTR7 (0.65) | NPSR1BLMRAD52HTR6HTR7 | |
| Serotonin SCHEMBL27310578 | 0.79 | HTR1D (0.78) | NPSR1BLMRAD52HTR6HTR7 | |
| SCHEMBL28100768 | 0.78 | HSD17B10 (0.64) | NPSR1BLMRAD52HTR6HTR7 | |
| SCHEMBL1320834 | 0.77 | HTR1D (0.67) | NPSR1BLMRAD52HTR6HTR7 | |
| SCHEMBL2003333 | 0.76 | KDM4E (0.75) | NPSR1BLMRAD52HTR6HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040191312-A1 | 5-HT3 receptor agonists as neuroprotectors | AGY THERAPEUTICS, INC. | 2004-09-30 | — | — | US | claimed |
| US-20020173511-A1 | Serotonergic compositions and methods for treatment of mild cognitive impairment | WURTMAN RICHARD J (US) | 2002-11-21 | — | — | US | claimed |
| WO-2002038142-A2 | SEROTONERGIC COMPOSITIONS AND METHODS FOR TREATMENT OF MILD COGNITIVE IMPAIRMENT | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2002-05-16 | — | — | WO | claimed |
| US-8058243-B2 | Method for treating a brain cancer with ifenprodil | HSC RESEARCH AND DEVELOPMENT LIMITED PARTNERSHIP (CA) | 2011-11-15 | — | — | US | disclosed |
| US-20090076019-A1 | METHODS FOR TREATING NEUROLOGICAL DISORDERS OR DAMAGE | MOUNT SINAI HOSPITAL (CA) | 2009-03-19 | — | — | US | disclosed |
| US-7013836-B1 | Enhancing maturation of oocytes in bivalves | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 2006-03-21 | — | — | US | disclosed |
| US-20040191312-A1 | 5-HT3 receptor agonists as neuroprotectors | AGY THERAPEUTICS, INC. | 2004-09-30 | — | — | US | disclosed |
| US-20030050226-A1 | Dopamine analog amide | SHASHOUA VICTOR E (US) | 2003-03-13 | — | — | US | disclosed |
| US-20020173511-A1 | Serotonergic compositions and methods for treatment of mild cognitive impairment | WURTMAN RICHARD J (US) | 2002-11-21 | — | — | US | disclosed |
| US-6407137-B2 | A PRODRUG COMPOUND CAPABLE OF FACILITATING THE PASSAGE OF A DRUG ACROSS THE BLOOD BRAIN BARRIER COMPRISING A FATTY ACID COUPLED TO A DRUG TO FORM A PRODRUG | PROTARGA, INC. | 2002-06-18 | — | — | US | disclosed |
| WO-2002038142-A2 | SEROTONERGIC COMPOSITIONS AND METHODS FOR TREATMENT OF MILD COGNITIVE IMPAIRMENT | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2002-05-16 | — | — | WO | disclosed |
| US-20010056116-A1 | Dopamine analog amide | LUITPOLD PHARMACEUTICALS, INC. | 2001-12-27 | — | — | US | disclosed |
| US-6258836-B1 | FATTY ACID COUPLED TO ANTIAIDS SUBSTANCE, ANTIBIOTIC, CHOLINERGIC AGONIST AND OTHER USES FOR PASSING THE BLOOD BRAIN BARRIER | PROTARGA, INC. | 2001-07-10 | — | — | US | disclosed |
| US-6107499-A | FACILITATING THE TRANSPORT OF A NEUROTRANSMITTER ACROSS THE BLOOD BRAIN BARRIER BY ADMINISTERING THE DRUG, A NEUROTRANSMITTER SUCH AS DOPAMINE COVALENTLY COUPLED TO A SINGLE, STRAIGHT-CHAINED FATTY ACID CARRIER MOLECULE | NEUROMEDICA, INC. (US) | 2000-08-22 | — | — | US | disclosed |
| US-5994392-A | PASSAGE OF DRUG THROUGH BLOOD BRAIN BARRIER | NEUROMEDICA, INC. (US) | 1999-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010056116-A1 | Dopamine analog amide | FABP7, SLC6A3, ALOX15 | HTR1A 34/4885HTR2C 90/4885ADRA2A 100/4885 |
| US-20040191312-A1 | 5-HT3 receptor agonists as neuroprotectors | HTR3A, HTR3B, HTR3E | HTR1A 6/4885HTR2C 13/4885ADRA2A 102/4885 |
| US-20030050226-A1 | Dopamine analog amide | FABP7, SLC6A3, ALOX15 | HTR1A 34/4885HTR2C 90/4885ADRA2A 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.